Charlotte Kamm

Charlotte Kamm

Auto-generated profile, based on publicly available information

Charlotte Kamm

Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for Infection Research (HZI), Würzburg D-97080, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2025 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
DGDarshana Gupta
Darshana Gupta
CPConstantinos Patinios
Constantinos Patinios
HBHarris V. Bassett
Harris V. Bassett
AKAnuja Kibe
Anuja Kibe
SCScott P. Collins
Scott P. Collins
CBChase L. Beisel
Chase L. Beisel
Base editors create precise genomic edits by directing nucleobase deamination or removal without inducing double-stranded DNA breaks. However, a vast chemical space of other DNA modifications remains to be explored for genome editing. Here we harness the bacterial antiphage toxin DarT2 to append ADP-ribosyl moieties to DNA, unlocking distinct editing outcomes in bacteria versus eukaryotes. Fusing an attenuated DarT2 to a Cas9 nickase, we program site-specific ADP-ribosylation of thymines within a target DNA sequence. In tested bacteria, targeting drives homologous recombination, offering flexible and scar-free genome editing without base replacement or counterselection. In tested yeast, plant and human cells, targeting drives substitution of the modified thymine to adenine or a mixture of adenine and cytosine with limited insertions or deletions, offering edits inaccessible to current base editors. Altogether, our approach, called append editing, leverages the addition of chemical moieties to DNA to expand current modalities for precision gene editing.

25 March 2026 in RNA
Verified
Journal Article
Open access
PDF file
JVJörg Vogel
Jörg Vogel
CKCharlotte Kamm
Charlotte Kamm
GGGiorgia Gerolimetto
Giorgia Gerolimetto
PMPranjal Meel
Pranjal Meel
ATAlexandre Trubert
Alexandre Trubert
CFChristian Fröschel
Christian Fröschel
RNAmed - Future Leaders in RNA-based Medicine is a unique graduate training program in the area of RNA-based medicine. Financed by the Free State of Bavaria, Germany, it is jointly run by several universities and research institutes from Würzburg, Regensburg and Munich. It aspires to equip doctoral students with a comprehensive idea of RNA therapeutics, spanning fundamental biology, translational research, clinical application, regulation, ethics, and societal implications. This integrative approach is meant to cultivate exceptional qualifications for careers across academia, industry, and policy. The RNAmed program held its 2025 annual retreat on San Servolo (Venice, Italy), with a total of 40 doctoral researchers, principal investigators (PIs), and invited guests from academia and pharmaceutical industry attending. The three-day program combined keynotes, student presentations, flash talks, a career panel and topic-table discussions of advances and challenges across RNA therapeutics to catalyze exchange and collaboration. Presentations highlighted emerging directions for antisense strategies, circular RNAs, delivery technologies, and AI-enabled molecular design, reflecting the program’s cross-disciplinary nature. Discussions emphasized shared priorities such as clear experimental standards, robust delivery solutions, and stronger academia–industry ties to accelerate safe, effective RNA medicines. Updates on RNAmed’s growth and extended funding underscored its mission to develop talent through integrated scientific and professional training. Overall, the retreat strengthened a network of early-career scientists and mentors committed to advancing RNA-based modalities from concept to clinic.